Publications by authors named "Sara Pracht"
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated toxin.
View Article and Find Full Text PDFArticle Synopsis
- Osteosarcoma is a serious type of bone cancer that mainly affects kids and young adults, and it can be hard to treat with standard methods.
- Researchers tested a new treatment called VSV-IFNβ-NIS on dogs with the same cancer to see if it could help improve survival rates.
- The treatment seemed safe and showed promise, as about 35% of the treated dogs lived longer, and they also had signs of strong immune responses against the cancer.
Article Synopsis
- Osteosarcoma is a serious bone cancer that mostly affects kids, teens, and young adults, and even with treatment, some patients get worse.
- A new treatment using a special virus called VSV-IFNβ-NIS was tested on dogs with this type of cancer before they had surgery, and it showed promising results.
- The treatment was safe, helped some dogs live longer, and boosted their immune systems to fight cancer better.
Objective: To explore relationships between 9-axis inertial measurement unit (IMU) output and activities of varying intensity in dogs of various sizes.
Animals: 20 healthy, agility course-trained dogs of various ages and sizes.
Procedures: Height, weight, body condition score, age, length from IMU to the ischium, and height of IMU to the floor were recorded.